Floatz logo

Nextgen-Til

Epithelial Tumors, Malignant

Vall d'Hebron Institute of OncologyCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Epithelial Tumors, Malignant cohort.

Asset / SponsorPhaseRating
TIPIRACIL
Academic and Community Cancer Research United
Phase 2B
Palbociclib
Academic and Community Cancer Research United
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 1/2B
Trifluridine
Academic and Community Cancer Research United
Phase 2B
Binimetinib
Academic and Community Cancer Research United
Phase 2B

View all 50 →

Same molecule, other indications

Nextgen-Til is also rated in:

Malignant Solid TumorDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →